摘要
基因导向性酶前体药物疗法(GDEPT)包括将负责原位转化前体药物成为细胞毒性代谢物的自杀基因靶向投递到肿瘤细胞中,这种方法应用到临床的主要限制是自杀基因的前药活化能力差。我们通过融合CYP2B6三突变体与NADPH细胞色素P450还原酶( CYP2B6TM -RED ),建立了一个能高效生物激活前体药物环磷酰胺(CPA)的自杀基因。这种融合基因的表达通过重组慢病毒(LV)载体转化抗人( A549 )和鼠( TC1 )肺细胞系进入CPA敏感的细胞系。我们在C57Bl/6免疫小鼠身上测试了我们的基因导向性酶前体药物治疗的效力,使用能够表达HPV-16 E6 / E7癌蛋白的TC1细胞。在仅由 TC1-CYP2B6TM-RED细胞构成的小鼠肿瘤上注射4次环磷酰胺后(140毫克/公斤,每周一次)能在两个月后完全根除肿瘤。含有25%TC1-CYP2B6TM-RED细胞构成的肿瘤也能在注射5次环磷酰胺后根除,展现了主要的体内旁观者效应。而且,存活的小鼠都被再次采用亲代TC1细胞进行测试。肿瘤在细胞接种后七日自然消退或是增长慢于对照组的未给药幼鼠,这是由于受到抗E7CD8 + T细胞介导的强烈的免疫反应。这些数据表明CYPB6TM -RED基因与CPA联合有望成为一种能非常有效治疗人类实体瘤的治疗手段。
关键词: 细胞色素P450 2B6,慢病毒,环磷酰胺,肺
Current Gene Therapy
Title:A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response
Volume: 14 Issue: 3
Author(s): Walid Touati, Thi Tran, Johanne Seguin, Monique Diry, Jean-Pierre Flinois, Claude Baillou, Geraldine Lescaille, Francois Andre, Eric Tartour, Francois M. Lemoine, Philippe Beaune and Isabelle de Waziers
Affiliation:
关键词: 细胞色素P450 2B6,慢病毒,环磷酰胺,肺
摘要: Gene-directed enzyme prodrug therapy (GDEPT) consists in targeted delivery to tumor cells of a suicide gene responsible for in situ conversion of a prodrug into cytotoxic metabolites. One of the major limitations of this strategy in clinical application was the poor prodrug activation capacity of suicide gene. We built a highly efficient suicide gene capable of bioactivating the prodrug cyclophosphamide (CPA) by fusing a CYP2B6 triple mutant with NADPH cytochrome P450 reductase (CYP2B6TM-RED). Expression of this fusion gene via a recombinant lentivirus (LV) vector converted resistant human (A549) and murine (TC1) pulmonary cell lines into CPA-susceptible cell lines. We tested the efficiency of our GDEPT strategy in C57Bl/6 immunocompetent mice, using TC1 cells expressing the HPV-16 E6/E7 oncoproteins. In mice bearing tumors composed only of TC1-CYP2B6TM-RED cells, four CPA injections (140 mg/Kg once a week) completely eradicated the tumors for more than two months. Tumors having only 25% of TC1-CYP2B6TM-RED cells were also completely eradicated by five CPA injections, demonstrating a major in vivo bystander effect. Moreover, surviving mice were rechallenged with parental TC1 cells. The tumors regressed spontaneously 7 days after cell inoculation or grew more slowly than in control naive mice due to a strong immune response mediated by anti-E7CD8+T cells. These data suggest that combining the CYPB6TM-RED gene with CPA may hold promise as a highly effective treatment for solid tumors in humans.
Export Options
About this article
Cite this article as:
Touati Walid, Tran Thi, Seguin Johanne, Diry Monique, Flinois Jean-Pierre, Baillou Claude, Lescaille Geraldine, Andre Francois, Tartour Eric, Lemoine M. Francois, Beaune Philippe and de Waziers Isabelle, A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response, Current Gene Therapy 2014; 14 (3) . https://dx.doi.org/10.2174/1566523214666140424152734
DOI https://dx.doi.org/10.2174/1566523214666140424152734 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Curcumin: Not So Spicy After All
Mini-Reviews in Medicinal Chemistry New Approach to Cancer Therapy: The Application of Signal Transduction to Anti-Cancer Drug
Current Medicinal Chemistry - Anti-Cancer Agents Pharmacological Modulation of Nitric Oxide Release: New Pharmacological Perspectives, Potential Benefits and Risks
Current Medicinal Chemistry Newer Avenues for the Treatment of Leptomeningeal Carcinomatosis
Central Nervous System Agents in Medicinal Chemistry The Use of Oncolytic Vaccinia Viruses in the Treatment of Cancer: A New Role for an Old Ally?
Current Gene Therapy Targeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective
Current Pharmaceutical Design Semaphorins and their Receptors in Stem and Cancer Cells
Current Medicinal Chemistry The Roles of Histone Demethylase UTX and JMJD3 (KDM6B) in Cancers: Current Progress and Future Perspectives
Current Medicinal Chemistry Angiogenesis in Glioblastoma Multiforme: Navigating the Maze
Anti-Cancer Agents in Medicinal Chemistry A Brief Review of the Essential Role of Nanovehicles for Improving the Therapeutic Efficacy of Pharmacological Agents Against Tumours
Current Drug Delivery ADAM8/MS2/CD156, an Emerging Drug Target in the Treatment of Inflammatory and Invasive Pathologies
Current Pharmaceutical Design Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Taxus-based Drug Development
Current Drug Metabolism The Role of miR-129-5p in Cancer: A Novel Therapeutic Target
Current Molecular Pharmacology Regulation of Cell Death and Survival by Resveratrol: Implications for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry RNA Splicing: Basic Aspects Underlie Antitumor Targeting
Recent Patents on Anti-Cancer Drug Discovery Tracking the Mesenchymal Stem Cell Fate After Transplantation Into the Infarcted Myocardium
Current Stem Cell Research & Therapy Cardiac ATP-Sensitive Potassium Channels: A Potential Target for an Anti-Ischaemic Pharmacological Strategy
Cardiovascular & Hematological Agents in Medicinal Chemistry [11C]Meta-Hydroxyephedrine PET/CT
Current Radiopharmaceuticals The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors
Current Pharmaceutical Design Design, Synthesis, and Transport Potential of a New Family of Nonionic Amphiphilic Dendro-calix[4]arene
Current Organic Chemistry